NeuroVenti contributes to creating a society where we work together.
NeuroVenti will continue to grow into a world-class company in the field
NeuroVenti is striving to develop the world's first autism therapeutics
Despite advances in medicine, neurodevelopmental disabilities, including autism spectrum
disorder (ASD), do not have adequate medicinal treatments as of yet, resulting to many
individuals and their families having to endure suffering. Based on more than 20 years of
research on developmental disorders, NeuroVenti is striving to develop the world's first
autism therapeutics through discovering innovative treatment candidates.
Due to the complex action of various neurotransmitters, neuromodulators, and hormones, as well as the effects of
various genetic and environmental risk factors and the interconnection of various brain regions underlying the pathophysiology of
neurodevelopmental disabilities, developing therapeutics for brain dysfunction through simple modulation of a single target,
as was believed to be sufficient in the past, could not provide an efficient way to tackle down the formidable challenge.
NeuroVenti's innovative target-control technology enables precise control of high-level brain 0functions,
which can be used for the treatment of intractable brain diseases, such as non-responsive depression, as well as
developmental disorders including ASD, ADHD, and Tourette's syndrome.
NeuroVenti is continuing research and development activities, with clinical success as its top priority,
through develop science-based medicinal treatments using the latest research knowledge and techniques in various fields such as medicine, pharmacy,
and molecular biology. NeuroVenti will continue to grow into a world-class company in the field of intractable brain disorders
through development of innovative treatments. We ask for your continued interest and support for NeuroVenti's
uninterrupted and vigorous steps that may contribute to creating a brain well-being society.